---
layout: post
title: "Statistical Approaches To Establishing Bioequivalence; Draft Guidance for Industry; Availability"
date: 2026-02-05 19:01:45 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-26414
original_published: 2022-12-05 00:00:00 +0000
significance: 8.00
---

# Statistical Approaches To Establishing Bioequivalence; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** December 05, 2022 00:00 UTC
**Document Number:** 2022-26414

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Statistical Approaches to Establishing Bioequivalence." This draft guidance provides recommendations to sponsors and applicants planning to use equivalence criteria in analyzing bioequivalence (BE) studies for investigational new drug applications (INDs), new drug applications (NDAs), abbreviated new drug applications (ANDAs), and supplements to these applications. The guidance discusses statistical approaches for BE comparisons and focuses on how to use these approaches both generally and in specific situations. When finalized, this guidance will replace FDA's 2001 guidance for industry of the same name.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/12/05/2022-26414/statistical-approaches-to-establishing-bioequivalence-draft-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2022-26414

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
